Schmitt, N.
Mokli, Y.
Weyland, C. S.
Gerry, S.
Herweh, C.
Ringleb, P. A.
Nagel, S.
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 29 April 2021
Revised: 3 September 2021
Accepted: 22 September 2021
First Online: 13 November 2021
Change Date: 17 August 2022
Change Type: Update
Change Details: The original version of this article was updated. Funding note "Open Access funding enabled and organized by Projekt DEAL" has been added.
Declarations
:
: The scientific guarantor of this publication is Simon Nagel.
: The authors of this manuscript declare relationships with the following companies: P.A.R.: Consultancy: Boehringer, Lecture fees from Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Pfizer. C.H.: Consultancy fees from Brainomix. S.N.: Consultancy fees and participation in Advisory Boards from and for Brainomix, lecture fees from Pfizer and Böhringer Ingelheim. All other authors have nothing to disclose.
: One of the authors (SG) has significant statistical expertise.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: • Retrospective• Diagnostic study• Performed at one institution